Top Biotech Stocks To Invest In Right Now

It was a decision a long time in the making, but the Food and Drug Administration has officially given Portola Pharmaceuticals’ (NASDAQ:PTLA) AndexXa the green light. The approval ends a winding road for the company that includes a regulatory rejection, a refiling for approval, and requests for additional information. With a go-ahead finally secured, is this biotech about to become a top stock to buy?

In this clip from The Motley Fool’s Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell discuss why AndexXa matters to this company’s investors.

A full transcript follows the video.

This video was recorded on May 9, 2018.

Kristine Harjes: We want to update you guys about Portola! [laughs] I hope our listeners aren’t sick of hearing us talk about this. I was thinking about it earlier today, I knew that we were going to be talking about Portola, and I wish we could make a metric that had captured a ratio between the number of minutes that we’ve spent discussing a stock on this show relative to that stock’s market cap, because Portola would be by far the highest. [laughs]

Top Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stocks 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stocks 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter?
    Sales of Alkermes’opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company’sschizophrenia drugAristadarose 62% to $29.2 million. Manufacturing and royalty revenue related toJohnson & Johnson’s schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related toAcorda Therapeutics’ multiple sclerosis drugfell3% to $28.3 million. Research and development revenue earned as part of its collaboration withBiogen (NASDAQ:BIIB) for BIIB098 — which used to be called ALKS 8700 — was $17.5 million.

    Looking beyond the financials, here’s an overview of the key events from the period:

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

  • [By WWW.GURUFOCUS.COM]

    For the details of Woodford Investment Management LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP

    These are the top 5 holdings of Woodford Investment Management LLPProthena Corp PLC (PRTA) – 11,557,614 shares, 37.95% of the total portfolio. Shares added by 0.25%Alkermes PLC (ALKS) – 5,270,428 shares, 27.32% of the total portfolio. Shares reduced by 30.52%Theravance Biopharma Inc (TBPH) – 10,898,879 shares, 23.64% of the total portfolio. Shares added by 1.41%Biogen Inc (BIIB) – 279,564 shares, 6.85% of the total portfolio. Shares reduced by 24.56%Evofem Biosciences Inc (EVFM) – 7,465,538

Top Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

Top Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
    Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

Top Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Cory Renauer]

    Sanofi took the assessment and started engaging end payers to see if any would offer easy reimbursement for a lower net price that reflects ICER’s assessment, and the industry listened. As of July 1, the partners will cut the net price of Praluent in return for straightforward access for around 25 million Americans covered by theExpress Scripts (NASDAQ:ESRX) national formulary. Thepharmacy benefits manager, and will also remove formulary access for its main competitor, Amgen’s (NASDAQ:AMGN) Repatha.

  • [By ]

    Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

  • [By Keith Speights]

    It’s not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.

Leave a Reply

Your email address will not be published. Required fields are marked *